STOCK TITAN

Zymeworks BC Inc - ZYME STOCK NEWS

Welcome to our dedicated news page for Zymeworks BC (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks BC.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zymeworks BC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zymeworks BC's position in the market.

Rhea-AI Summary
Zymeworks Inc. (ZYME) to report first quarter 2024 financial results and host a conference call for a corporate update on May 2, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences earnings
-
Rhea-AI Summary
Zymeworks Inc. announces five presentations at the 2024 AACR Annual Meeting, showcasing new data on their preclinical development programs. Highlights include ZW191, a FRα-targeting ADC with strong preclinical activity, and TriTCE Co-Stim, a trispecific T cell engager platform designed to improve responses in treating solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
-
Rhea-AI Summary
Zymeworks Inc. appoints Dr. Neil Gallagher to its board of directors, bringing over 20 years of experience in drug development in the oncology field. Dr. Gallagher's expertise will support Zymeworks' '5 by 5' programs and pipeline expansion of novel therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
management
Rhea-AI Summary
Zymeworks Inc. (ZYME) announces participation in several upcoming investor conferences to discuss their diverse pipeline of novel biotherapeutics. Management will present at the 23rd Annual Needham Virtual Healthcare Conference, Canaccord Genuity Horizons in Oncology Virtual Conference, Stifel Virtual Targeted Oncology Days Conference, and 2024 Bloom Burton & Co. Healthcare Investor Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
conferences
-
Rhea-AI Summary
Zymeworks Inc. reported $456.3 million in cash resources as of December 31, 2023, ensuring projected cash runway into 2H 2027. The company initiated a rolling BLA filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers in the US. Multiple Phase 3 trials and regulatory submissions are planned for zanidatamab globally. Zymeworks highlighted progress in its R&D programs, including the development of novel biotherapeutics and IND submissions for new product candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
-
Rhea-AI Summary
Zymeworks Inc. announces acceptance of five abstracts for poster presentations at AACR Annual Meeting, highlighting strong progress in developing antibody-drug conjugates and multispecific antibody therapeutics. The company's ZW191 shows promising preclinical activity, while next-generation trispecific T cell engager platforms demonstrate durable anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences clinical trial
Rhea-AI Summary
Zymeworks Inc. (ZYME) will participate in investor conferences to showcase its diverse pipeline of biotherapeutics for difficult-to-treat diseases. The company will present at TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
conferences
-
Rhea-AI Summary
Zymeworks Inc. (ZYME) will report its Q4 2023 financial results on March 6, 2024, followed by a conference call and webcast to discuss financial results and corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences earnings
-
Rhea-AI Summary
Zymeworks Inc. announced the appointment of Dr. Alessandra Cesano to its board of directors, succeeding Dr. Kenneth Hillan. Dr. Cesano brings over 25 years of experience in drug development, diagnostics, and cancer immunology. She will help advance the company's pipeline of novel antibody-drug conjugates and multispecific antibodies. Dr. Cesano currently serves as a director at Puma Biotechnology and Summit Therapeutics, and as the Chief Medical Officer of ESSA Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
management
Rhea-AI Summary
Zymeworks Inc. (ZYME) announced its participation in upcoming investor conferences, including Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, Oppenheimer 34th Annual Healthcare Life Sciences Conference, and Citi's 2024 Virtual Oncology Leadership Summit. The company aims to present its diverse pipeline of novel biotherapeutics for difficult-to-treat diseases, with the management participating in one-on-one meetings and fireside chats. The presentations and webcasts will be available on Zymeworks’ website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
Zymeworks BC Inc

Nasdaq:ZYME

ZYME Rankings

ZYME Stock Data

652.76M
41.59M
4.49%
96.15%
7.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver

About ZYME

zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.